[go: up one dir, main page]

MX2022000937A - Mitorriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas. - Google Patents

Mitorriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas.

Info

Publication number
MX2022000937A
MX2022000937A MX2022000937A MX2022000937A MX2022000937A MX 2022000937 A MX2022000937 A MX 2022000937A MX 2022000937 A MX2022000937 A MX 2022000937A MX 2022000937 A MX2022000937 A MX 2022000937A MX 2022000937 A MX2022000937 A MX 2022000937A
Authority
MX
Mexico
Prior art keywords
mitochondrial
mitoriboscins
bacteria
cancer cells
pathogenic yeast
Prior art date
Application number
MX2022000937A
Other languages
English (en)
Inventor
Michael P Lisanti
Federica Sotgia
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of MX2022000937A publication Critical patent/MX2022000937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)

Abstract

La presente descripción se refiere a inhibidores de la función mitocondrial. Se dan a conocer métodos de prospección de los compuestos para la inhibición mitocondrial. También se describen métodos para usar inhibidores mitocondriales llamados mitorriboscinas - compuestos terapéuticos basados en mitocondrias que tienen propiedades anti-cancerosas y antibióticas - para prevenir o tratar el cáncer, infecciones bacterianas y levadura patógena, así como también métodos para usar inhibidores mitocondriales para proporcionar beneficios antienvejecimiento. También se dan a conocer compuestos específicos de mitorriboscina y grupos de mitorriboscinas.
MX2022000937A 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas. MX2022000937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471688P 2017-03-15 2017-03-15
PCT/US2018/022403 WO2018170109A1 (en) 2017-03-15 2018-03-14 Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast

Publications (1)

Publication Number Publication Date
MX2022000937A true MX2022000937A (es) 2022-10-21

Family

ID=63523316

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019010759A MX390968B (es) 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas
MX2022000937A MX2022000937A (es) 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas.
MX2022000938A MX2022000938A (es) 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019010759A MX390968B (es) 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000938A MX2022000938A (es) 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas.

Country Status (23)

Country Link
US (4) US11311501B2 (es)
EP (1) EP3596043B1 (es)
JP (2) JP7104134B2 (es)
KR (1) KR102623283B1 (es)
CN (1) CN110621655B (es)
AU (2) AU2018235937A1 (es)
BR (1) BR112019019109B1 (es)
CA (1) CA3056086A1 (es)
CL (1) CL2019002580A1 (es)
CO (1) CO2019010027A2 (es)
CR (2) CR20190458A (es)
CU (3) CU20190079A7 (es)
DO (3) DOP2019000230A (es)
EC (1) ECSP19073204A (es)
IL (2) IL305316B2 (es)
MX (3) MX390968B (es)
NZ (1) NZ756854A (es)
PE (1) PE20191485A1 (es)
PH (1) PH12019502056B1 (es)
RU (1) RU2019132396A (es)
SG (1) SG11201908487YA (es)
WO (1) WO2018170109A1 (es)
ZA (5) ZA201905970B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2744989B2 (ja) 1992-07-24 1998-04-28 光洋機械工業株式会社 小径工作物の外径寸法測定システム
US20220339125A1 (en) * 2017-03-15 2022-10-27 Lunella Biotech, Inc. Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
US11561227B2 (en) 2017-10-11 2023-01-24 Lunella Biotech, Inc. Anti-mitochondrial inhibitors for oncogenic Ras and Myc
WO2019232161A1 (en) 2018-06-01 2019-12-05 Lunella Biotech, Inc. Biomarkers and therapeutics for endocrine therapy resistance
JP7538119B2 (ja) 2018-10-02 2024-08-21 ルネラ・バイオテック・インコーポレーテッド 老化細胞死誘導薬としてのアジスロマイシンおよびロキシスロマイシン誘導体
JP7641897B2 (ja) 2018-12-17 2025-03-07 ルネラ・バイオテック・インコーポレーテッド 抗加齢のための三剤組合せ療法
BR112021011963A2 (pt) * 2018-12-17 2021-09-08 Lunella Biotech, Inc. Terapias de combinação tripla para alvejamento de mitocôndria e exterminação de células-tronco de câncer
CA3136811A1 (en) * 2019-04-16 2020-10-22 Lunella Biotech, Inc. Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments
CA3141610A1 (en) 2019-05-24 2020-12-03 Lunella Biotech, Inc. Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer
WO2021214727A1 (en) 2020-04-24 2021-10-28 Lunella Biotech, Inc. Therapeutic methods for preventing tumor metastasis and tumor recurrence

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2062025A (en) * 1931-12-19 1936-11-24 Harrington Joseph Method and apparatus for treating moisture-containing substances
US2059764A (en) * 1933-11-03 1936-11-03 Zerillo Frank Pneumatic tire
US2058655A (en) * 1934-10-12 1936-10-27 Borg Warner Friction clutch
JPS537424B2 (es) * 1971-10-08 1978-03-17
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2000001433A (ja) 1998-06-11 2000-01-07 Pfizer Pharmaceuticals Inc ５―リポキシゲナ―ゼ阻害剤
GB0323585D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
US7932242B2 (en) * 2004-03-16 2011-04-26 Temple University - Of The Commonwealth System Of Higher Education Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
US8778874B2 (en) * 2004-11-29 2014-07-15 National University Corporation Nagoya University Glycopeptide antibiotic monomer derivatives
CN101495113A (zh) * 2006-04-21 2009-07-29 史密丝克莱恩比彻姆公司 Il-8受体拮抗剂
CA2680583A1 (en) * 2007-03-15 2008-09-25 Schering Corporation Pyridazinone derivatives useful as glucan synthase inhibitors
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
JP6068803B2 (ja) * 2009-01-29 2017-01-25 コー，ヤング，ヒー 癌治療用組成物及び癌治療方法
CN102439453A (zh) * 2009-05-20 2012-05-02 日内瓦大学 癌症起始细胞的线粒体活性抑制剂及其用途
EA025611B1 (ru) 2010-07-29 2017-01-30 Райджел Фармасьютикалз, Инк. Активирующие ampk гетероциклические соединения и способы их использования
US20140288077A1 (en) * 2011-07-05 2014-09-25 St. Jude Children's Research Hospital Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
CN102886054B (zh) * 2011-07-19 2014-04-02 复旦大学 一种抑制细菌信号转导系统PhoQ组氨酸激酶活性的制剂
EP2950649B1 (en) * 2013-02-01 2020-03-04 Wellstat Therapeutics Corporation Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
CA2884607A1 (en) * 2015-03-11 2016-09-11 Stealth Peptides International, Inc. Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions

Also Published As

Publication number Publication date
JP2020514418A (ja) 2020-05-21
IL269309A (en) 2019-11-28
IL269309B1 (en) 2023-09-01
AU2022205218A1 (en) 2022-08-04
US20210186898A9 (en) 2021-06-24
US11364210B2 (en) 2022-06-21
ZA202101517B (en) 2023-01-25
PE20191485A1 (es) 2019-10-18
NZ756854A (en) 2022-02-25
US11311501B2 (en) 2022-04-26
JP2022133418A (ja) 2022-09-13
WO2018170109A1 (en) 2018-09-20
KR20190130595A (ko) 2019-11-22
DOP2022000165A (es) 2022-11-30
RU2019132396A (ru) 2021-04-15
ZA202001040B (en) 2021-08-25
RU2019132396A3 (es) 2021-04-15
EP3596043B1 (en) 2025-12-03
CN110621655B (zh) 2023-03-10
US20200060998A1 (en) 2020-02-27
US20200170967A1 (en) 2020-06-04
MX2022000938A (es) 2022-12-14
BR112019019109B1 (pt) 2023-11-07
PH12019502056A1 (en) 2020-07-06
DOP2019000230A (es) 2020-01-31
JP7104134B2 (ja) 2022-07-20
DOP2022000164A (es) 2022-11-30
AU2018235937A1 (en) 2019-09-19
CU20190096A7 (es) 2020-10-20
IL305316B2 (en) 2024-09-01
IL305316A (en) 2023-10-01
KR102623283B1 (ko) 2024-01-11
CL2019002580A1 (es) 2020-02-14
SG11201908487YA (en) 2019-10-30
CR20190458A (es) 2019-12-18
ZA202001041B (en) 2021-10-27
ZA201905970B (en) 2021-01-27
CU20190097A7 (es) 2020-10-20
US10512618B2 (en) 2019-12-24
AU2022205218B2 (en) 2023-11-23
CO2019010027A2 (es) 2019-09-30
EP3596043A1 (en) 2020-01-22
JP7312891B2 (ja) 2023-07-21
CN110621655A (zh) 2019-12-27
IL269309B2 (en) 2024-01-01
CR20220381A (es) 2022-09-15
US20190091181A1 (en) 2019-03-28
CU20190079A7 (es) 2020-04-02
US11547679B2 (en) 2023-01-10
MX390968B (es) 2025-03-21
PH12019502056B1 (en) 2024-04-17
BR112019019109A2 (pt) 2020-04-22
ZA202203603B (en) 2023-12-20
US20210130370A1 (en) 2021-05-06
ECSP19073204A (es) 2019-10-31
MX2019010759A (es) 2019-12-11
CA3056086A1 (en) 2018-09-20
IL305316B1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
PH12019502056A1 (en) Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12020550476A1 (en) Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration
MY188541A (en) Besifloxacin for the treatment of resistant acne
MY197635A (en) Benzooxazole derivatives as immunomodulators
MX382562B (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub).
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EP4292650A3 (en) Heterocyclic compounds as immunomodulators
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
MX2023004221A (es) Inhibidores de rad51.
EP4353254A3 (en) Methods for treating skin infection by administering an il-4r antagonist
MX2019007613A (es) Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos.
PH12019502892A1 (en) Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
PH12019501780A1 (en) Microbial cells, methods of producing the same, and uses thereof
EP4241844A3 (en) Compositions for topical treatment of microbial infections
MX2016015218A (es) Antibioticos macrociclicos de amplio espectro.
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
MX2018005348A (es) Composiciones y metodos para transduccion de tumores.
PH12016501988A1 (en) Antibacterial compounds
NZ735398A (en) Novel n-acyl-arylsulfonamide derivatives as aminoacyl-trna synthetase inhibitors
ZA202006612B (en) Antibacterial compounds
MX2018006190A (es) Antibioticos de amplio espectro macrociclico.
AU2017272405A1 (en) Imidazolone compounds as human Neutrophil Elastase inhibitors